A Phase 1b-2 Study to Evaluate Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Erdafitinib Plus JNJ-63723283, an Anti-PD-1 Monoclonal Antibody, in Subjects With Metastatic or Surgically Unresectable Urothelial Cancer With Selected FGFR Gene Alterations
Phase of Trial: Phase I/II
Latest Information Update: 03 Feb 2019
At a glance
- Drugs Cetrelimab (Primary) ; Erdafitinib (Primary)
- Indications Urogenital cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms NORSE
- Sponsors Janssen Research & Development
- 06 Dec 2018 Planned End Date changed from 22 Jun 2023 to 30 Nov 2022.
- 14 Sep 2018 Planned End Date changed from 15 Oct 2020 to 22 Jun 2023.
- 31 Aug 2018 Biomarkers information updated